On the heels of a successful share placement in July, Oxford BioMedica Plc is moving its gene therapy and cancer vaccine programmes ahead with a near-term focus on completing the dosing of patients in a Phase 1 study of a gene therapy for ‘wet’ age-related macular degeneration (AMD).
